Martin S. Dyer

Leicester, ENG LE19HN, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 99 publications

More than an attachment module: covalent inhibitor warheads influence BTK dynamics and function.

More than an attachment module: covalent inhibitor warheads influence BTK dynamics and function.

Journal: bioRxiv : the preprint server for biology

Published: May 18, 2026

The spectrum of immunoglobulin heavy chain enhancer hijacking in chronic lymphocytic leukemia.

The spectrum of immunoglobulin heavy chain enhancer hijacking in chronic lymphocytic leukemia.

Journal: Leukemia

Published: October 27, 2025

What does BCL-2 do? From new molecular insights to the clinical implications.

What does BCL-2 do? From new molecular insights to the clinical implications.

Journal: Cell death and differentiation

Published: July 29, 2025

Chronic lymphocytic leukemia with IGH::BCL3-translocation is characterized by a homogeneous and distinct genetic and epigenetic landscape.

Chronic lymphocytic leukemia with IGH::BCL3-translocation is characterized by a homogeneous and distinct genetic and epigenetic landscape.

Journal: HemaSphere

Published: July 29, 2025

Targeted Degradation of Class 1 HDACs With PROTACs is Highly Effective at Inducing DLBCL Cell Death.

Targeted Degradation of Class 1 HDACs With PROTACs is Highly Effective at Inducing DLBCL Cell Death.

Journal: EJHaem

Published: May 31, 2025

The BH3-only protein NOXA is essential for apoptosis induction by BH3-mimetics targeting BCL2 or BCL-XL in DLBCL.

The BH3-only protein NOXA is essential for apoptosis induction by BH3-mimetics targeting BCL2 or BCL-XL in DLBCL.

Journal: British journal of haematology

Published: May 23, 2025

The unfolded protein response influences therapy outcome and disease progression in chronic lymphocytic leukaemia.

The unfolded protein response influences therapy outcome and disease progression in chronic lymphocytic leukaemia.

Journal: Scientific reports

Published: March 26, 2025

Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemia.

Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemia.

Journal: eLife

Published: December 27, 2024

In vitro comparison of CD20xCD3 bispecific antibodies against diffuse large B-cell lymphoma (DLBCL) cell lines with different levels of expression of CD20.

In vitro comparison of CD20xCD3 bispecific antibodies against diffuse large B-cell lymphoma (DLBCL) cell lines with different levels of expression of CD20.

Journal: British journal of haematology

Published: November 28, 2024

Long-term outcomes of chemoimmunotherapy with obinutuzumab/chlorambucil in chronic lymphocytic leukemia.

Long-term outcomes of chemoimmunotherapy with obinutuzumab/chlorambucil in chronic lymphocytic leukemia.

Journal: Blood advances

Published: September 20, 2024

The chromosomal translocation t(1;6)(p35.3;p25.2), recurrent in chronic lymphocytic leukaemia, leads to RCC1::IRF4 fusion.

The chromosomal translocation t(1;6)(p35.3;p25.2), recurrent in chronic lymphocytic leukaemia, leads to RCC1::IRF4 fusion.

Journal: British journal of haematology

Published: July 24, 2024

Monitoring of molecular responses to tirabrutinib in a cohort of exceptional responders with relapsed/refractory mantle cell lymphoma.

Monitoring of molecular responses to tirabrutinib in a cohort of exceptional responders with relapsed/refractory mantle cell lymphoma.

Journal: EJHaem

Published: May 08, 2024

Showing 1-12 of 99

Last Updated: 09/26/2026